Dr Reddys Laboratories Ltd
DRREDDY Share Price
BSE:500124
NSE:DRREDDY
₹1148.1
-3.90 (-0.34%)
Performance
Loading performance...
Fundamentals
About
Dr Reddy's Laboratories Ltd is India’s top multinational pharmaceutical companies. Headquartered in Hyderabad, with U.S. operations in New Jersey, the company manufactures over 190 medications, 60 active pharmaceutical ingredients (APIs), diagnostic kits, and biotechnology products. Founded by Kallam Anji Reddy, it started as a supplier to Indian drug makers and gradually expanded into global markets. Approval in regulated markets like the U.S. and Europe strengthened its growth which is also reflected in Dr Reddy's Laboratories Ltd share price.
History of Dr Reddy's Laboratories Ltd Share Price
Founded in 1984, Dr Reddy's began with active pharmaceutical ingredients and soon launched branded drugs like Norilet and Omez. By 1987, it became the first Indian company to export APIs to Europe. Expansion into regulated markets, FDA-approved plants, and diversified products contributed to consistent growth, shaping Dr Reddy's Laboratories Ltd share price over the years.
Financial Performance of Dr. Reddy’s Laboratories
Dr Reddy share price reflects the performance of one of India’s leading pharmaceutical companies. As of today, Dr Reddy share price on NSE and BSE shows the market’s response to the company’s steady growth. The company has reported strong revenue and healthy operating margins, supporting investor confidence.
Revenue & Profit: Q3 FY26 revenue rose 4.4% YoY to ₹87.3 billion, while net profit fell 14% to ₹12.1 billion due to pricing pressures.
Margins & Efficiency: EBITDA margin remains high at 28.3%; cash conversion cycle is 36 days.
Debt: Total debt stood at ₹60.36 billion.
Growth Drivers: Investments in biosimilars, oncology, new product launches, and strategic partnerships continue to boost Dr Reddy’s laboratories share price.
Investors tracking Dr Reddy share price today can consider its consistent financial performance and long-term growth potential on both the NSE and BSE.
Business Segments of DR. Reddy’s Laboratories Ltd
Dr. Reddy’s Laboratories Ltd operates through key business segments that drive growth.
Global Generics (GG): Core segment producing prescription and OTC medicines, biosimilars, and branded generics. Major markets include the USA, India, Russia, and Europe.
Pharmaceutical Services and Active Ingredients (PSAI): Focuses on manufacturing APIs and intermediates, including services through Aurigene Pharmaceutical Services (APSL) for drug discovery and development.
Proprietary Products & Others: Covers niche formulations, new chemical entities, and digital health products.
Other Initiatives: Expansion into consumer health, nutrition, and advanced technologies like cell and gene therapy.
These segments together help maintain steady revenue growth and support Dr Reddy share price today.
Subsidiaries of Dr. Reddy’s Laboratories Ltd
Dr. Reddy’s Laboratories Ltd operates through a wide global network of over 50 subsidiaries, supporting its growth and influencing Dr Reddy share price BSE.
Key International Subsidiaries
USA: Dr. Reddy's Laboratories Inc., Trigenesis Therapeutics, Inc.
Europe: Dr. Reddy's Laboratories (EU) Limited (UK), betapharm Arzneimittel GmbH (Germany), Dr. Reddy's Laboratories Romania SRL
Emerging Markets: Dr. Reddy's Farmaceutica Do Brasil Ltda (Brazil), Dr. Reddy's Laboratories (Proprietary) Ltd (South Africa), Dr. Reddy's Laboratories (Thailand) Ltd
Other Regions: Dr. Reddy's Laboratories Canada, Inc., Dr. Reddy's Laboratories (Australia) Pty. Limited
Notable Subsidiaries: Aurigene Discovery Technologies, Idea2Enterprises (India) Private Limited
This global presence helps Dr. Reddy’s maintain revenue growth and strengthens Dr Reddy share price. The performance of each division and the company’s other strategic actions help drive Dr Reddy share price NSE and BSE performance, reflecting the company’s consistent growth and investor confidence.
| Name | Designation |
|---|---|
| Satish Reddy | Chairman & Exec. Director |
| G V Prasad | Co-Chairman & Managing Director |
| Leo Puri | Independent Non Exe. Director |
| Shikha Sharma | Independent Non Exe. Director |
| Anupam Puri | Director |
| J P Moreau | Director |
| KODUMUDI PRANATHARTHIHARAN KRISHNAN | Independent Non Exe. Director |
| Kalpana Morparia | Director |
| Pennv Wan | Independent Non Exe. Director |
| Omkar Goswami | Director |
| Arun M. Kumar | Independent Non Exe. Director |
| Claudio Albrecht | Independent Non Exe. Director |
| Ravi Bhoothalingam | Director |
| Sandeep Poddar | Company Secretary |
| ALPNA HANSRAJ SETH | Independent Non Exe. Director |
| Bruce L A Carter | Director |
| Sanjiv Mehta | Independent Non Exe. Director |
| Ashok Sekhar Ganguly | Director |
| Srikanth Ramakrishna Velamakanni | Independent Non Exe. Director |
| K Randhir Singh | CS / CO / Head - CSR |
| Sridar Iyengar | Additional Director |
Dr Reddys Laboratories Ltd FAQs
How do I Buy Dr Reddys Laboratories Ltd Shares?
By opening a demat account and having your KYC papers confirmed online, you may simply purchase Dr Reddys Laboratories Ltd shares in BlinkX.
What is the Share Price of Dr Reddys Laboratories Ltd?
The share price of any stock is volatile and changes during the day due to a variety of variables. Dr Reddys Laboratories Ltd's share price is ₹1148.1 as of 2026-08-03.
What is the PE ratio of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd's P/E ratio is 29.73 times as of 2026-08-03.
What is the PB ratio of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd's most recent financial reports indicate a price-to-book ratio of 2.52, showing the company's stock market valuation in relation to the value of its real assets.
What is the Market Cap of Dr Reddys Laboratories Ltd?
Market capitalization, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Dr Reddys Laboratories Ltd's market capitalization is ₹95787.39 Cr as on 2026-08-03.
What is the ROE of Dr Reddys Laboratories Ltd?
The current financial records of Dr Reddys Laboratories Ltd show a 10.69% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.
What is the Total Asset of Dr Reddys Laboratories Ltd?
According to Dr Reddys Laboratories Ltd's most recent financial filings, the company has a total asset value of ₹15486.6, which includes current and non-current assets such as inventory, cash, properties, and equipment.
What is the 52-week high and Low of Dr Reddys Laboratories Ltd?
The 52-week high/low price of a Dr Reddys Laboratories Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Dr Reddys Laboratories Ltd's 52-week high and low as of 2026-08-03 are ₹1414.9 and ₹1101, respectively.
